The expertise of Orano in advanced nuclear technologies has enabled the development of a method for the stable extraction of high-purity lead-212. Already used in the research against cancer, this radioactive isotope coming from the decay chain of thorium-232, was all too rare. This shortage was hampering research on alpha therapy. At present, two lead-212 production units in France and the United States offer an invaluable supply for the medical community and the pharmaceutical industry